*Fumiyoshi Morikawa¹, Sayuri Matuzaki¹, Mayumi Munekata¹, Megumi Ootawa¹, Kana Asada¹, Musashi Tachibana¹, Takeshi Hasukawa¹, Toshiya Maruyama¹, Takafumi Tezuka¹, Tomonori Murayama¹, Yuuta Sekinou¹, Kazuki Tabata¹, Sachiko Sirakawa¹, Mitutaka Inomata¹, Juichirou Naoe¹ (1. Asahikawa Keisenkai hospital)

*Fumihiro Tomoda¹, Atsumi Nitta², Tsutomu Tsutomu ³, Hiroko Sugimori³, Hiroko Kurosaki ³ (1. The Faculty of Health Science, Fukui Health Science University, 2. The Department of Pharmaceutical Therapy & Neuropharmacology, University of Toyama , 3. The Second Department of Internal Medicine, University of Toyama)

Ken Inada¹, Yoshitaka Saito¹, Kenji Baba², Daisuke Fukui³, Yuriko Masuda⁴, Sachie Inoue⁴, *Takahiro Masuda² (1. Department of Psychiatry, Kitasato University School of Medicine, 2. Medical Science, Sumitomo Pharma Co., Ltd., 3. Global Data Design Office, Sumitomo Pharma Co., 4. CRECON Medical Assessment Inc)

Takahiro Nemoto^1,2, Miyuki Okumura³, Fumiya Sano³, *Hidenori Maruyama³ (1. Department of Neuropsychiatry, Toho University Faculty of Medicine, 2. Department of Psychiatry and Implementation Science, Toho University Faculty of Medicine, 3. Sumitomo Pharma Co., Ltd.)

*Kazushige Watabe¹ (1. Tamiya hospital)

*Wataru Omori^1,2, Naoto Kajitani^2,3, Mami Okada-Tsuchioka², Shuken Boku³, Minoru Takebayashi^2,3 (1. Department of Psychiatry, Hiroshima University Hospital, 2. Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3. Department of Neuropsychiatry, Faculty of Life Science, Kumamoto University)

Yoshiteru Takekita¹, *Yuji Matsumoto², Takahiro Masuda², Kazumasa Yoshida³, Yosuke Koshikawa¹, Masaki Kato¹ (1. Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, 2. Medical Science, Sumitomo Pharma Co., Ltd., 3. Data Science, Sumitomo Pharma Co., Ltd.)